The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
about
Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsStereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juiceEvidence of impaired cisapride metabolism in neonatesInfluence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride.Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.Review article: cardiac adverse effects of gastrointestinal prokinetics.Macrolide drug interactions: an update.Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycinRisk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.Drug-drug interactions in pharmacologic management of gastroparesis.Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactionsRisk assessment of mechanism-based inactivation in drug-drug interactions.Antimicrobial-associated QT interval prolongation: pointes of interest.Increase in mortality rate following coprescription of cisapride and contraindicated drugs.Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.Part 6. Pediatric advanced life support: 2015 Korean Guidelines for Cardiopulmonary Resuscitation.Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes.Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.Antibiotic-induced cardiac arrhythmias.Blockage of hERG current and the disruption of trafficking as induced by roxithromycin.Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats.Magnitude, mechanism, and reproducibility of QT interval differences between superimposed global and individual lead ECG complexes.Effects of macrolide antibiotics on rat embryonic heart function in vitro.Use of cisapride with contraindicated drugs in The Netherlands.Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study.Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization.Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem.Observations on conducting whole-cell patch clamping of the hERG cardiac K+ channel in pure human serum.Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
P2860
Q28071256-A422509B-6573-4CCF-99D5-2681479A51ECQ28362551-E1343F73-48D1-4A1E-AD32-D95FE130C16DQ28362557-C904C3E7-4F67-4315-B6A5-2F6FB68A5298Q32049802-5FFF5045-3B28-467C-BE56-BC5B7A91339BQ33147807-DF4ED0A3-DCBD-4A45-B4AC-FC969129D02AQ33695220-F3EBB7DA-AE10-4346-9C99-BE27C6C02AE6Q33792373-9AB4627B-37B7-46D4-9C44-23EF766A33C0Q33895235-6048ECA7-6E8A-4038-8B52-E6E14BFEE440Q34049823-C32B4171-0815-4C59-9E71-439AD89D7BD4Q34186776-506D2028-F514-4D9B-B69B-80CA8BFEDD27Q34480053-083DBDDB-440B-466F-BF9C-D06DF2BF0135Q35042153-DB1D70E9-1D53-4685-A959-10EB89315A99Q36174265-806B0A7C-F413-4CDD-84FD-8C43C73E51EAQ36655034-DC3E0C21-719A-4ADE-9372-B26AB2EEC1A4Q36765263-87E8BFFB-5868-438E-95CC-786391F0F46BQ36808701-F4CB12E7-24C7-4445-8AE0-A613C9E47817Q37315740-CCFD5F82-4765-40BB-895C-427735E0EBD5Q37765087-79674C34-21DF-4798-A44E-E363BAFB2D2EQ38030582-39F61E48-6ACC-4AF8-A14E-312F212B50C5Q38178757-12F092EA-F0D5-42D7-AFCC-E0148C23F943Q39052111-FCF574BE-5FBD-4018-9D7B-84645E7732FAQ39475200-B2AC758A-2CB8-42ED-AB3F-9AAE82EF8D54Q39802290-B872D389-8A34-4217-BC8B-6988A931A94DQ40209609-4031878B-51F4-4366-B4E0-3ED4ACC897FDQ43888420-A365D46C-75E9-44F9-BEDF-C92A8E8EE439Q44039631-508EA996-BB02-41EC-A3D3-8C78E4B88C40Q44582898-AF96436E-6FEA-4F1F-9FF8-3C421F08040FQ46109640-63BA0498-A9AA-4DB3-B02A-2EF3FEBCFCB5Q48017483-C184DF81-9496-4CFA-9544-485556D9CFE8Q53256610-052365E8-F0A3-4070-8E71-9FDA9EAA3E5A
P2860
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
@en
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
@nl
type
label
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
@en
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
@nl
prefLabel
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
@en
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.
@nl
P2093
P1476
The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
@en
P2093
Burggraaf J
van 't Klooster GA
van Gerven JM
van Haarst AD
van Oene JC
P304
P356
10.1016/S0009-9236(98)90137-0
P407
P577
1998-11-01T00:00:00Z